Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,836
  • Shares Outstanding, K 5,862
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,580 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.19
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -33.90
  • Most Recent Earnings $-1.81 on 11/14/25
  • Next Earnings Date 11/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.76
  • Growth Rate Est. (year over year) +56,861.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7106 +16.10%
on 11/19/25
3.3096 -75.07%
on 11/06/25
-2.1850 (-72.59%)
since 11/05/25
3-Month
0.7106 +16.10%
on 11/19/25
5.9000 -86.02%
on 09/16/25
-3.8850 (-82.48%)
since 09/05/25
52-Week
0.7106 +16.10%
on 11/19/25
108.0000 -99.24%
on 01/13/25
-20.7750 (-96.18%)
since 12/05/24

Most Recent Stories

More News
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP 3 ACT™ platform, show excellent in silico free energy binding to the viral target entry protein,...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates that its...

SLRX : 0.8250 (-5.23%)
Salarius: Q3 Earnings Snapshot

Salarius: Q3 Earnings Snapshot

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Strategic transaction supports the advancement of Decoy’s rapid computational design and manufacturing of innovative peptide conjugate therapeutics through its IMP 3 ACT™ platform Combined...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

HOUSTON , Nov. 11, 2025 /PRNewswire/ -- Salarius Pharmaceuticals, Inc. ("Salarius" or the "Company") (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Regains Nasdaq Compliance for Merger

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Salarius...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Awaits Nasdaq Compliance Confirmation

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Salarius...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The...

SLRX : 0.8250 (-5.23%)
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer...

SLRX : 0.8250 (-5.23%)

Business Summary

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and...

See More

Key Turning Points

3rd Resistance Point 0.9707
2nd Resistance Point 0.9403
1st Resistance Point 0.8827
Last Price 0.8250
1st Support Level 0.7947
2nd Support Level 0.7643
3rd Support Level 0.7067

See More

52-Week High 108.0000
Fibonacci 61.8% 67.0154
Fibonacci 50% 54.3553
Fibonacci 38.2% 41.6952
Last Price 0.8250
52-Week Low 0.7106

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar